Brii Bio Initiates Submission of Emergency Use Authorization Filing to U.S. FDA for BRII-196/BRII-198, its Monoclonal Antibody Combination Therapy for Non-Hospitalized COVID-19 Patients at High Risk of Clinical Progression to Severe Disease

PR Newswire
October 9, 2021 — 03:07 CST

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!

Already have an account or paid subscription? Log in

Related Topics: africa Argentina Beijing biotech brazil China Covid-19 healthcare Hong Kong investment manufacturing medicine Mexico Philippines South Africa United States

Related News:

Evolving Global Asset Management Industry in Focus at Asset Abu Dhabi

December 11, 2024 — 02:10

Crystal clear: Pingcheng period glassware of Northern Wei Dynasty

November 9, 2024 — 08:00

Harbour BioMed Announces Submission of IND Application for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease

November 8, 2024 — 17:45

LPS Launches NeuroNode: Empowering Advanced AI for Enterprises with On-Premises LLM

November 7, 2024 — 17:39

Live from ESMO 2024 | Ascentage Pharma Releases Latest Data Showing Sustained Clinical Efficacy of Olverembatinib in SDH-Deficient GIST during a Mini Oral Presentation

September 14, 2024 — 08:18

Desay Battery Highlights Advanced Energy Solutions at RE+ 2024

September 11, 2024 — 03:00

Transcenta Holding Limited (Stock Code: 6628.HK) Announce 2024 Interim Results

August 29, 2024 — 14:31

Telin and Indosat Ooredoo Hutchison Partner to Develop the Indonesia Cable System Express 2 (ICE System 2)

August 28, 2024 — 20:46

LAZADA GROUP RELEASES ANNUAL ENVIRONMENTAL, SOCIAL AND GOVERNANCE (ESG) IMPACT REPORT FOR FINANCIAL YEAR 2024

August 27, 2024 — 11:00

Franchising and Licensing Asia (FLAsia) 2024